Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2022-07-15 Major Shareholding Noti…
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2022-07-15 English
PRE 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed with the SEC, pursuant to Section 14(c) of the Securities Exchange Act of 1934. It informs stockholders of a corporate action taken by written consent related to a PIPE Financing transaction, including issuance of shares and warrants to the majority stockholder. The document explicitly states it is an Information Statement, not a proxy solicitation, and is provided to inform stockholders of the action taken without a meeting. The content focuses on shareholder approval of a private placement and compliance with Nasdaq Listing Rules. This type of filing is a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to inform them about corporate actions and solicit their consent or inform them of consent obtained without a meeting. It is not an Annual Report, Earnings Release, or Capital/Financing Update per se, but a formal SEC filing under Schedule 14C. The document length (15,000 characters) and detailed content confirm it is the statement itself, not just an announcement. Therefore, the correct classification is PSI with high confidence.
2022-07-15 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 15, 2022, by BioVie Inc. It reports the entry into a material definitive agreement, specifically a securities purchase agreement for a private placement of common stock and warrants. The document details the terms of the private placement, the parties involved, and the expected closing date. It also includes references to exhibits such as the purchase agreement and warrant form. The content focuses on a financing transaction and capital raising activity. Given the nature of the filing (Form 8-K) and the detailed description of a securities purchase agreement and private placement, this document fits the category of Capital/Financing Update (CAP). The document length (6176 characters) and detailed content confirm it is not merely an announcement but a substantive report of the financing event.
2022-07-15 English
Director's Dealing 2022
Director's Dealing
2022-07-07 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 28, 2022, by BioVie Inc. The key content is an update to the company's investor presentation, which is furnished as Exhibit 99.1. The text explicitly states that the investor presentation is incorporated by reference and available on the company's website. There is no detailed financial data or comprehensive report content within this filing; rather, it is an announcement of the updated investor presentation. According to the classification rules, announcements about presentations or reports that are attached or referenced but not included in full should be classified as Regulatory Filings (RNS) or Report Publication Announcements (RPA). However, since this is a Form 8-K specifically furnishing an updated investor presentation and the presentation is included as an exhibit, the most appropriate classification is Investor Presentation (IP). The document is not a full financial report, earnings release, or other report type, but an update and furnishing of an investor presentation. Confidence is high given the explicit mention and nature of the filing.
2022-06-29 English
FORM 10-Q FOR PERIOD ENDING MARCH 31, 2022
Interim / Quarterly Report Q3 2022
2022-05-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.